- Unlock the 99.9% Unknown: Our proprietary AI decodes unmapped microbial DNA that traditional methods miss, discovering novel biomarkers beyond the reach of reference-based approaches
- Improve Drug Response Rates: Stratify patients to double efficacy while reducing side effects for non-responders
- Ready-to-License Assets: Validated biomarkers already developed for major biologics
- Over 100,000 novel biomarkers already discovered: demonstrated efficacy prediction in large-scale animal study as well as human Crohn’s and Colitis trial.
Dr. Yaniv Altshuler
Dr. Altshuler is an MIT researcher and an experienced entrepreneur, renowned for his expertise in designing and implementing scalable AI systems. Dr. Altshuler is the author of three books on the theory of Artificial Intelligence, as well as over 80 scientific papers, and 18 patents in this field. His novel work has gained global recognition, including the prestigious title of Technological Pioneer awarded by the World Economic Forum.
Alphabiome AI
Website: https://www.alphabiome.ai/
Alphabiome is pioneering a new approach to decoding the microbiome and predicting drug response using advanced AI. Our platform delivers proprietary, IP-protected biomarkers backed by robust human data, ready for direct licensing.
Founded by MIT AI experts and Stanford Nobel Laureates in genetics, the company has already discovered over 100,000 novel biomarkers. The technology has been validated in large-scale animal trials and shown proof-of-concept in humans, with recent breakthroughs in predicting drug efficacy for Crohn’s and Colitis.
